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SUMMARY 
Chemo-radiotherapy is primary treatment in patients with squamous cell carcinoma of the 
anus (SCCA) but variations in trial outcome reporting have limited between-study comparisons 
and hindered evidence synthesis. Treatment-related morbidity is considerable, yet no trial has 
comprehensively quantified long-term side-effects or quality of life. To address these issues, 
we established the first international health care professional (HCP)-patient consensus to 
develop a core outcome set, using the COMET methodology. We conducted a systematic 
review and patient interviews to derive a comprehensive list of outcomes, followed by a two-
round Delphi survey completed by 149 participants from 11 countries (patients, 55; HCPs, 94). 
The Delphi results were discussed at a combined HCP-patient consensus meeting, where 
agreement was reached on 19 core outcomes across four domains: Disease activity, survival, 
toxicity, life impact. Implementation of the Core Outcome Research Measures in Anal Cancer 
(CORMAC) set in future trials will serve as an overall framework to capture a core of relevant, 
standardised outcomes across four domains, facilitate selection of health area-specific 
evaluation tools; reduce redundancy of lengthy outcome lists; allow outcome comparisons; 
and ultimately enhance the relevance of trial findings to HCPs, trialists and patients.  
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INTRODUCTION 
The incidence of squamous cell carcinoma of the anus (SCCA) has increased globally over 
the last 3 decades1, most markedly in high income countries, where (world) standardised 
incidence rates range from 0.4 to 1.8 per 100,000.   Historically, primary treatment of SCCA 
was by radical surgical resection, but a paradigm shift occurred in the 1970s and 1980s when 
small studies demonstrated high rates of local control with primary radiotherapy, with or 
without chemotherapy,2,3 and an opportunity for anal sphincter preservation. Subsequently, 
six phase III randomised trials (2877 patients) in Europe and the USA established the 
effectiveness of chemoradiotherapy as primary treatment.4-9 Over this period, survival 
progressively improved; currently 5-year overall survival rates approach 75%.10 However, this 
success has come at the cost of considerable treatment-related acute and long-term toxicity.  
Across the above six trials, there is considerable variation in trial outcome reporting limiting 
between-study comparisons and hindering evidence synthesis.11 Furthermore, outcomes in 
these trials were primarily related to survival and disease activity; no trial comprehensively 
addressed long-term side effects or quality of life (QoL). Both of these issues can be 
addressed by the development of a core outcome set (COS) “an agreed, standardised set of 
outcomes to be measured and reported, as a minimum, in all trials in a particular health 
area”12. COS have been endorsed as a means to reduce outcome heterogeneity, and to 
increase the relevance of research through involvement of key stakeholders in COS 
development13. This paper describes the development of a COS for trials of chemo-
radiotherapy interventions for SCCA.  
 
METHODS 
Scope 
The scope of the core outcome set to be developed has been defined according to the criteria 
recommended by COMET 14. 
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Health condition: Non-recurrent, non-metastatic squamous cell carcinoma of the anus/ anal 
canal (SCCA) 
Population: Adults >18 years of age 
Types of Interventions: Primary treatment with chemoradiotherapy 
Setting: Later phase trials that will inform clinical decision making 
Study overview 
The COS was developed in three phases, inclusive of patients and health professionals at 
each stage: (1) A long-list of outcomes was generated through systematic review15 and semi-
structured patient interviews; (2). The outcome long-list was used to populate the 2-phase 
Delphi process; (3) The results of the Delphi survey were reviewed at a face-to-face 
consensus meeting and a final COS determined.  
 
Phase 1: Information Gathering 
Search strategy and selection criteria 
Full details of the systematic review, including search strategy, databases and selection 
criteria have been published elsewhere.15 Outcomes and accompanying definitions were 
extracted verbatim from included studies and categorised into domains.  
Semi-structured interviews 
Outcomes of importance to patients were identified through semi-structured interviews. This 
approach uses open questions to facilitate a patient-led discussion, guided by additional 
prompts from a pre-prepared topic guide to ensure key areas are covered. Patient participants 
for the semi-structured interviews were identified and recruited from the Christie NHS 
Foundation Trust (Manchester, United Kingdom) anal cancer database and through the 
Macmillan anal cancer forum,16 following a purposive sampling matrix defined a priori.  
Eligibility criteria and the sampling matrix are available in the study protocol.17 Written informed 
consent was obtained before interviews. Outcomes were identified both indirectly through 
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listening to patients’ experiences and directly by asking about information needs before, during 
and after treatment. Audio recordings of the interviews were transcribed in full and coded to 
identify outcomes.  
Long-list generation 
Outcomes from the systematic review and patient interviews were combined. The long-list of 
outcomes, accompanied by relevant quotes from the patient interviews, was discussed by the 
CORMAC Study Advisory Group (SAG, described below) (September 2017). For each 
outcome, the group agreed (i) merging with closely related items and; (ii) exclusion if 
considered to be of limited clinical importance (for example, extremely rare events) and were 
not identified in the patient interviews. (iii) face validity and domain allocation. The final 
outcome list was used to populate the Delphi questionnaire. Outcomes were converted into 
question items, with clinical and plain language versions, which were reviewed for face validity, 
understanding and acceptability by the Christie NHS Foundation Trust Patient Information 
Committee (comprising health professionals and lay members) and modified according to 
feedback. 
Phase 2: Delphi Survey 
The Delphi survey was run using the online DelphiManager platform.18 Participants were 
recruited from the two key stakeholder groups: patients and health care professionals (HCPs). 
Clinical researchers involved in clinical trials formed a subgroup within the HCP stakeholder 
group. Patient were recruited from four UK treatment centres, via social media (Twitter) and 
patient advocacy groups (Supplementary file S1).  Patients were asked to confirm that they 
had received or were receiving treatment with chemoradiotherapy for SCCA in a declaration 
when registering to take part in the Delphi. HCPs were recruited by direct e-mail to principal 
investigators in the PLATO (PersonaLising Anal cancer radioTherapy dOse) trial19 and via UK 
and international professional organisations (Supplementary file S1). Eligibility criteria are 
detailed in the study protocol. The Delphi process was conducted over 2 rounds (termed R1 
and R2). In each round, participants were asked to rate the importance of including each 
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outcome in the COS on a 1-9 scale described as: Limited importance (1-3); important but not 
critical (4-6); and critically important (7-9). Participants could suggest additional outcomes at 
the end of R1which were reviewed by the core team (RF, CS, AGR and PRW); any outcome 
not already represented was added to R2. No outcomes were dropped between rounds. In 
R2, participants were shown a histogram of the R1 scores for each outcome together with 
their own R1 score, before being asked to reflect on the information presented and score each 
outcome again. 
The percentage of participants scoring each of 1-9 was calculated from the R2 scores for each 
outcome. Consensus criteria were defined a priori:12 outcomes scored as ‘critically important’ 
(7-9) by ≥70% of patients and ≥70% of HCPs, and ‘limited importance’ (1-3) by ≤15% of 
patients and ≤15% of HCPs were defined as ‘consensus in’ and included in the provisional 
COS. Outcomes scored 1-3 by ≥70% and 7-9 by ≤15% of both stakeholder groups were 
defined as ‘consensus out’ and were excluded. Outcomes not fulfilling criter ia for consensus 
in or out were defined as ‘no consensus’.  
Phase 3: Consensus Meeting 
The results of the Delphi survey were presented at a face-to-face consensus meeting. 
Participants were eligible to attend if they had completed both rounds of the Delphi survey. 
Participants were sampled purposively to promote balanced representation of patients and 
HCPs of differing disciplines. International participation was capped for budgetary reasons. 
Prior to the meeting, all participants were sent a summary of their own Delphi R2 scores. The 
meeting was chaired by an independent, non-clinical researcher with expertise in COS 
development methodology (SB), and not a member of the SAG.  
Outcomes identified in R2 of the Delphi as ‘consensus in’ were presented first and participants 
asked if there were any fundamental reasons why these should not be included in the COS. 
Outcomes deemed ‘consensus out’ were reviewed and participants asked if there were any 
fundamental reasons why these should be included in the COS. All ‘no consensus’ outcomes 
were discussed and voted on with outcomes where one stakeholder group had scored ≥70% 
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7-9 considered first. Remaining ‘no consensus’ outcomes were reviewed together, with 
individual outcomes being discussed and voted on only if proposed as being important by a 
meeting participant. Contrasting views were actively sought and the chair ensured all 
participants had equal opportunity to contribute before voting commenced. Voting was 
conducted anonymously using TurningPoint© software and handsets (Turning Technologies 
LLC, Youngstown, USA). Voting followed the same format as in the Delphi, with results 
displayed to participants immediately for each outcome. Outcomes meeting the criteria for 
‘consensus in’ were included in the COS; all other items were dropped. At the end of the 
meeting, the final COS was presented to participants and ratified.  
 
Other analyses  
We assessed for attrition bias between Delphi R1 and R2, comparing the distribution of mean 
R1 scores for participants did and did not complete R2 12. We assessed for consensus meeting 
participation bias by comparing the distribution of mean R2 scores for participants who did 
and did not participate in the consensus meeting. To assess satisfaction with the process and 
outcome of the consensus meeting, we collected questionnaire feedback from participants, 
(Supplementary file S2). 
 
Ethics and registration 
Our findings are reported in line with the Core Outcome Set-Standards for Reporting (COS-
STAR) reporting guidance.20 This project was prospectively registered with the COMET 
initiative (Core Outcome Measures in Effectiveness Trials).21 The study protocol and 
composition of the SAG have been published elsewhere.17 The study was approved by the 
National Research Ethics Service: Semi-structured interviews: IRAS ID 183034, CPMS study 
ID 20368, adopted January 2016; Delphi and consensus meeting: IRAS ID 215791, CPMS 
Study ID: 33052; adopted February 2017.  
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RESULTS 
An overview of the CORMAC COS development process and of the final COS is shown in 
figure 1.  
 
Phase I: Information Gathering 
The systematic review has been described in detail elsewhere [16]. In brief,1243 outcomes 
were identified from 101 studies, consolidated into 92 standardised outcome terms.  Interviews 
with 19 patients identified 61 57 outcomes, including eight not identified from the literature 
(skin pain, skin itch, sleep disturbance, bone/joint pain, fertility, menopause, ejaculatory 
function and orgasmic function). The 100 standardised outcome terms were categorised into 
five domains (survival; disease activity; life impact; delivery of care; and toxicity). which can 
be directly mapped to the outcome domain taxonomy recommended by COMET22. After 
discussion by the SAG, 73 standardised outcome terms were taken forward into the Delphi 
process; one outcome was expanded into two and 28 were removed.  Full details of the 
outcomes excluded along with the reasons are available in supplementary file S3.   
 
Phase 2: Delphi Process 
One hundred and forty-nine participants from 11 countries (patients 55; HCPs 94) completed 
both rounds of the Delphi process. Participant characteristics are shown in Table 1. Thirty 
additional outcomes were proposed during R1, of which five were added into R2, and two 
outcome descriptions were revised (supplementary file S4). The full list of Delphi question 
items is available in supplementary file S5. 
The R2 results are summarised in Table 2. Fourteen outcomes met the criteria for ‘consensus 
in’. No outcomes met the original criteria for ‘consensus out’ so it was agreed by the SAG to 
redefine the criteria for ‘consensus out’ to a majority rule; outcomes were classed as 
‘consensus out’ if ≤50% of participants in both stakeholder groups scored the item as critically 
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important (7-9). Thirteen outcomes met the revised criteria for ‘consensus out’. The Delphi R1 
and R2 scores individual outcome are shown in supplementary file S6 and S7. 
The attrition rate from R1 to R2 was 18% (14% HCPs; 25% patients). Comparison of mean 
R1 scores for participants who did and did not complete both rounds suggested that those 
who did not complete R2 may have been more likely to score all outcomes more highly than 
those continuing to R2 (Figure 2A).  
 
Phase 3: Consensus Meeting  
Twenty-three HCPs and 13 patients participated in the consensus meeting (supplementary 
file S8). Comparison of the mean R2 scores of participants attending to those not attending 
the consensus meeting shows no evidence of any participation bias (Figure 2B). 
During discussions, participants suggested that different aspects of sexual function may be 
important to different people, with the result that no individual outcome would reach the 
threshold for inclusion despite broad agreement that sexual function overall should be 
included. Participants proposed and agreed through voting that all sexual function related 
outcomes be grouped together under a single broader outcome ‘sexual function’. This term 
mirrors other functional outcomes considered (physical, emotional, role/occupational and 
social function). This was subsequently validated on examination of the R2 results, which 
show that 80% (44/55) of patients and 71% (67/94) of HCPs scored 7-9 for at least one 
outcome in the sexual and reproductive toxicity domain. 
The results of voting for each outcome are shown in Table 3.The new ‘sexual function’ 
outcome and 4 ‘no consensus’ outcomes from the Delphi reached the criteria for ‘consensus 
in’ and were included in the final COS. Six outcomes that did not reach the threshold for 
‘consensus in’ were scored as critically important (7-9) by ≥70% of patients (cognitive function, 
emotional function, occupational/role function, anal pain, gastrointestinal (anorectal) bleeding 
and vaginal toxicity). 
During analysis of the consensus meeting voting results, we noted one HCP had erroneously 
self-allocated to the patient group. If they had selected the correct stakeholder group, it is 
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possible that one outcome (sexual function) may not have reached 70% 7-9 in the HCP group 
and would therefore not have been included in the COS. Since only one out of the 14 
participants in the self-allocated patient group scored this outcome less than seven, the 
probability of correct self-allocation changing the results is only 7% (1/14). Additionally, the 
final core outcome set was reviewed and agreed by all participants at the close of the 
consensus meeting. We therefore recommend that the original results stand. 
The final COS (Figure 1) includes 19 outcomes across four domains (6 disease activity; 5 
survival; 5 toxicity; 3 life impact). These were: treatment response, local failure, regional 
failure, distant failure, disease progression, salvage surgery, overall survival, cancer-specific 
survival, disease-free survival, metastasis-free survival, progression-free survival, anal 
incontinence, faecal urgency, pelvic fistula, stoma, skin loss, physical function, sexual 
function, and health-related QoL.  
The feedback questionnaire was completed by 74% (17/23) HCPs and all patients. All patient 
participants and 16/17 HCPs were comfortable communicating their views during the meeting 
(one HCP was ambivalent). All patients and 15/17 HCPs agreed that the meeting produced a 
fair result. The remaining HCPs deferred judgement until the final report was produced. 
Participants from both stakeholder groups commended the meeting for facilitating discussion 
between HCPs and patients. 
 
DISCUSSION 
Main findings 
Our study is the first international combined HCP-patient consensus on outcomes for trials in 
SCCA. All the included outcomes were all identified as critically important by over 70% of both 
patients and HCPs, using consensus methods which ensured representation of these groups 
on an equal footing. We recommend that all future trials evaluating chemo-radiotherapy for 
SCCA utilise the COMRAC COS as a framework for outcome selection. 
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In context with other literature 
We have not identified any other published COS for anal cancer. Glynne-Jones et al23 
previously identified the need for consensus on outcome definitions in anal cancer trials, but 
made recommendations based on the view of the authors without direct involvement of 
patients or the wider community of HCPs. In contrast, both patients and a broad range of 
HCPs have been involved in each stage of the development of this COS.  
In our initial systematic review linked to this consensus,15 we identified more than ten different 
survival or survival composite outcome terms in use, all with varying definitions. With the 
exception of overall survival, no survival outcome was reported in every randomised trial, and 
none has a single agreed definition. This heterogeneity reflects the lack of consensus (until 
now) on which survival endpoints to capture other than overall survival.  
There were some unexpected inclusions and exclusions in the final COS. Colostomy-free 
survival, which has been commonly used in trials in this field, was not selected as a core 
outcome, but colostomy was. This illustrates the pitfalls of creating composite outcomes; even 
when the events used to create a composite outcome are of interest, relevance of the 
composite cannot be assumed. The difficulties of defining progression-free survival (PFS) and 
its validity as marker for improved survival or QOL have been widely discussed,11,15,24-26 
however PFS is included in the CORMAC COS, indicating that it holds relevance to both 
patients and HCPs. In the next phase of the project, we will work to agree standardised 
definitions for the included outcomes. 
The new EORTC QOL module, ANL-27,27 is an anal cancer-specific patient reported outcome 
measure (PROM) developed and validated in a large international cohort of patients, which 
identifies the patient reported toxicity and functional outcomes which impact HRQOL in SCCA. 
The EORTC project aimed solely to evaluate the factors influencing HRQOL and did not 
evaluate patient (or HCP) views on survival or disease activity outcomes. By contrast, the 
present COS will serve as an overall framework to capture a wide range of agreed outcomes 
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in future trials. The outcomes in the CORMAC COS were derived through a transparent, 
inclusive, consensus process, from a comprehensive list of all possible outcomes, generated 
through systematic review and interviews with patients. The 19 outcomes included in the final 
COS (Figure 1) fall across four domains.   
Strengths and limitations 
The CORMAC study has a number of strengths. Our methodology is coherent with 
recommendations from an international consensus,28  and was clearly defined a priori in a 
protocol.17 Inclusion of both patients and HCPs at every stage ensured that outcomes in the 
final core set fairly represent their shared priorities. A unique strength of our consensus 
meeting, highlighted in the participant feedback, was directly bringing together patients and 
HCPs, enabling each group to hear the others’ views, facilitating open discussion. We ensured 
that the views of both stakeholder groups were represented equally, despite difference in the 
number of participants in each group, by applying the same consensus criteria to electronic 
voting as was used in the Delphi survey. Our comprehensive and rigorous longlisting process 
ensured that outcomes across all domains (survival, disease activity, life impact including 
HRQOL, toxicity and delivery of care) were considered during the consensus process. 
There are some limitations to this study. Due to time and budgetary constraints, our project 
was conducted only in English. Despite this, our Delphi process included patient and HCP 
participants from 11 countries. The attrition rate for patient participants in the second round of 
our Delphi is slightly higher than in other recent COS projects,29-31 possibly affected by the 
recruitment methods used. To maximise international reach, we disseminated Delphi 
invitations via social media and group e-mails through patient advocacy groups, with 62% of 
all patient participants being recruited via these channels. This group had the highest attrition 
rate, 33%, compared to 15% in those recruited via hospital sites, suggesting that participants 
recruited in this way are not as invested in the process as those recruited through personal 
contact. 
Clinical implications 
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It is important to acknowledge the interplay between outcomes in the toxicity and life impact 
domains. The toxicity domain relates to physiological outcomes including symptoms, whereas 
the life impact domain relates to the functional items and composite measures of HRQOL. At 
the consensus meeting, both HCPs and patients described the functional impact of the 
included toxicity outcomes. However, patient participants also described the value of specific 
toxicity outcome data, for example, the incidence and duration of symptoms, in addition to 
measures of impact. Therefore, we feel that it is important to maintain the distinction between 
these two domains.  
The life impact outcomes in the CORMAC COS include physical and sexual function as well 
as the composite measure of HRQOL. It is likely that the life impact and toxicity outcomes 
included in the CORMAC COS are factors in HRQOL in SCCA, but identifying the 
determinants of HRQOL was not the aim of this project and there are outcomes not included 
in the COS which influence HRQOL, as demonstrated by ANL-27.27 The concordance 
between the toxicity and life impact outcomes included in the CORMAC COS and the question 
items included in ANL-27 makes it likely that ANL-27 will be recommended as the preferred 
measurement instrument for these core outcomes. However, definitive recommendations 
cannot be made until full evaluation of available instruments has been completed in next phase 
of the CORMAC project. 
There were six outcomes that were not included in the final COS that at the consensus meeting 
were rated as critically important by patients, but not critically important by HCPs (Table 3). 
However, a COS is a minimum set of outcomes that should be included in trials in a particular 
field. The issues identified as of key importance to patients, including those not reaching the 
threshold for inclusion in the COS, can be used to aid the selection of additional outcomes of 
interest and to guide the research agenda going forward.  A COS should also be reviewed 
periodically to determine whether any excluded outcomes should be added or any included 
outcomes removed.12  
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Patient reported outcome Measures (PROMs) in Oncology 
Toxicity outcome reporting in trials for SCCA interventions and in oncology in general has 
historically been poor, with toxicity outcomes frequently reported only in non-specific terms 
such as ‘gastro-intestinal toxicity’ or ‘acute toxicity’.15 The clinician-reported CTCAE (Common 
Terminology Criteria for Adverse Events) system is the most widely used tool for measuring 
toxicity in oncology trials 32, including anal cancer trials 15. However, there are no guidelines 
for the clinical application of a given toxicity grading system, such as methods of patient 
screening or data collection 33 and trial reports rarely describe these methods in any detail. 33. 
Clinician reporting of symptomatic toxicity outcomes has been shown to lack reliability34 and 
under-estimate the incidence and severity of symptoms compared to patients’ direct reports.35-
37 Recognition of these issues has led to the development of new instruments for direct patient 
reporting of toxicity outcomes, such as PRO-CTCAE38 and eRAPID.39 However, such patient-
reported outcomes measures do not necessarily include patient-important outcomes, and the 
issue of selecting which toxicity outcomes to measure in a given trial has yet to be adequately 
addressed. The eRAPID system has selected a number of outcomes frequently experienced 
during treatment for five of the most common cancers. Therefore, toxicities encountered during 
treatment for rare cancers, such as anal cancer, may not be represented. The PRO-CTCAE 
system is derived from the CTCAE and includes a comprehensive library of 124 symptomatic 
toxicity outcomes from which trialists can construct bespoke PROMs by selecting applicable 
question items. To-date, there are no recommended outcome subsets specific to SCCA. By 
identifying the toxicities of critical importance to patients and HCPs, the CORMAC COS will 
facilitate selection of health area-specific evaluation tools in future trials increasing relevance 
and reducing redundancy.  
Future challenges and research 
Efforts will be needed to promote and monitor uptake of this COS. The COMET Initiative works 
to promote COS utilisation,40 and trial funding bodies, regulatory authorities and guideline 
development groups, such as the (UK) National Institute for Health Research, the European 
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Medicines Agency and the (UK) National Institute for Health and Care Excellence, now actively 
endorse the use of COS. Searches of trial registries41,42 identify five phase II and two phase 
III clinical trials of interventions for SCCA that are recruiting or opening soon. We recommend 
that the trial management groups (TMGs) of these studies review the CORMAC COS to 
consider if any changes to trial outcome measurement should be made to accommodate the 
recommended core outcomes. The most recent of the phase III trials, PLATO,19  commenced 
recruitment in the United Kingdom in 2017 and aims to evaluate both dose de-escalation in 
early stage and dose escalation in locally advanced disease. There is already considerable 
overlap between the outcomes specified in the PLATO trial protocol and the CORMAC COS. 
Development of this COS involved participation of stakeholders from 11 different countries, 
however further work should be undertaken to validate this COS more widely, especially in 
non-English speaking populations. Finally, the CORMAC COS describes which outcomes 
should be included in future clinical trials in SCCA. To ensure quality and consistency in 
measurement and reporting of these outcomes, in the next phase of this project we will work 
to agree standardised definitions and recommended measurement instruments for each 
outcome in the COS, following the approach recommended by the COSMIN (Consensus-
based Standards for the selection of health Measurement Instruments)/COMET 
collaboration.43  
 
Conclusion 
The outcomes included in the CORMAC COS represent the consensus opinion of an 
international group of patients, healthcare professionals and trialists and addresses an unmet 
need, assisting trialists in the design, conduct and reporting of future trials. Implementation of 
the CORMAC COS will ultimately enhance the relevance of trial findings to HCPs, trialists and 
patients.  
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